Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)

Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)

BackgroundNon–vitamin K antagonist oral anticoagulants (NOACs) are indicated for stroke prevention in atrial fibrillation (AF) but require lower doses in certain patients. We sought to describe the frequency, appropriateness (according to Food and Drug Administration labeling), and outcomes of patie...

Full description

Bibliographic Details
Main Authors: Benjamin A. Steinberg, Peter Shrader, Karen Pieper, Laine Thomas, Larry A. Allen, Jack Ansell, Paul S. Chan, Michael D. Ezekowitz, Gregg C. Fonarow, James V. Freeman, Bernard J. Gersh, Peter R. Kowey, Kenneth W. Mahaffey, Gerald V. Naccarelli, James A. Reiffel, Daniel E. Singer, Eric D. Peterson, Jonathan P. Piccini
Format: Article
Language:English
Published: Wiley 2018-02-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
atrial fibrillation
dosing
non–vitamin K antagonist oral anticoagulant
outcome
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.117.007633

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.117.007633

Similar Items